ARCALYST ® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth ARCALYST 2025 expected net product revenue raised to $670 - $675 million KPL-387 granted Orphan Drug Designation for the treatment of pericarditis Cash balance increased by $44.3 million in Q3 2025 to $352.1 million Conference call and webcast scheduled for 8:30 am ET today LONDON, Oct. 28, 2025 (GLOBE NEWSWIRE) --... Read More

LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern Time to report its third quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com.... Read More

LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis, which includes recurrent... Read More

LONDON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferences in September: Citi 2025 Biopharma Back to School Summit on Wednesday, September 3 at 9:00 a.m. Eastern Time 2025 Wells Fargo Healthcare Conference on Thursday, September 4 at 9:30 a.m. Eastern Time A live webcast of... Read More

ARCALYST ® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth ARCALYST 2025 expected net product revenue increased to $625 - $640 million KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated; Phase 2 data expected in 2H 2026 Cash balance increased by $39.4 million in Q2 2025 to $307.8 million Conference call and webcast scheduled for 8:30 am ET today LONDON,... Read More

LONDON, July 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its second quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com.... Read More

KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 KPL-387 Phase 1 single ascending dose data support profile for monthly dosing Presentation and webcast at Jefferies 2025 Global Healthcare Conference scheduled for 12:50 pm ET today LONDON, June 05, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and... Read More

LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the following investor conferences in June: Jefferies 2025 Global Healthcare Conference on Thursday, June 5 at 12:50 p.m. Eastern Time Goldman Sachs 46 th Annual Global Healthcare Conference on Tuesday, June 10 at 8:00 a.m. Eastern Time – Fireside Chat A live webcast of Kiniksa’s... Read More

Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that is often underdiagnosed or misdiagnosed LONDON, April 30, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing... Read More

ARCALYST ® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth ARCALYST 2025 expected net product revenue increased to $590 - $605 million KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 Current operating plan expected to remain cash flow positive on an annual basis Conference call and webcast... Read More

LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com.... Read More

ARCALYST ® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively ARCALYST 2025 net product revenue expected to be $560 - $580 million KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025; Phase 2 data expected in 2H 2026 Abiprubart development in Sjögren’s Disease to be discontinued Current operating plan expected to remain cash... Read More

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 KPL-387 Phase 1 single ascending dose data support potential monthly dosing Kiniksa continues to focus development on diseases with unmet need, prioritizing cardiovascular indications Kiniksa to discontinue abiprubart development in Sjögren’s Disease LONDON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals... Read More

LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at... Read More

ARCALYST ® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth ARCALYST 2025 net product revenue expected to be $560 - $580 million Kiniksa expects to remain cash flow positive on an annual basis LONDON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of... Read More

LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event... Read More